Rufinamide (E2080) + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Lennox-Gastaut Syndrome
Conditions
Lennox-Gastaut Syndrome
Trial Timeline
Jun 1, 2010 → Aug 1, 2011
NCT ID
NCT01146951About Rufinamide (E2080) + Placebo
Rufinamide (E2080) + Placebo is a phase 3 stage product being developed by Eisai for Lennox-Gastaut Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT01146951. Target conditions include Lennox-Gastaut Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01146951 | Phase 3 | Completed |
Competing Products
6 competing products in Lennox-Gastaut Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Placebo + Perampanel | Eisai | Phase 3 | 77 |
| Rufinamide | Eisai | Pre-clinical | 23 |
| Rufinamide | Eisai | Phase 3 | 77 |
| Rufinamide + Any other approved Antiepileptic Drug | Eisai | Phase 3 | 77 |
| Clobazam | Lundbeck | Phase 3 | 74 |
| GWP42003-P | Jazz Pharmaceuticals | Approved | 82 |